Chemotherapy Induced Anemia
Chemotherapy-induced anemia (CIA) is a consequence of the malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. The pathogenesis of Chemotherapy-induced anemia is complex and is often difficult to identify, and most of the time is multifactorial.
Chemotherapy Induced Anemia Epidemiology Segmentation in the 7MM
● Incident Cases of Chemotherapy-induced Anemia
● Severity-specific Cases of Chemotherapy-induced Anemia
● Incidence of Chemotherapy-induced Anemia per chemo cycles
Chemotherapy Induced Anemia Epidemiological Insights Observed in the 7MM (2021)
- The total incident cases of Chemotherapy Induced Anemia in the 7MM were observed to be 1.6 Million in the year 2021
- The highest Chemotherapy Induced Anemia incident population was found to be 728K cases in the EU5 in year 2021
- Chemotherapy Induced Anemia incident population was found to be 489K cases in the United States, in 2021
- Chemotherapy Induced Anemia incident population was found to be 384K cases in Japan, in year 2021
The market size of Chemotherapy Induced Anemia in the 7MM was found to be approximately USD 1,061.9 million in 2021.
Chemotherapy Induced Anemia Market Strengths
Challenges in treating anemic patients have given rise to a novel class of agents – HIF-PH inhibitors – that can change the existing anemia treatment paradigm.
Chemotherapy Induced Anemia Market Opportunities
Limited products in the pipeline to treat Chemotherapy-induced Anemia pave the way for companies to develop novel therapies that can modify patient outcomes and positively impact the quality of life of Chemotherapy-induced Anemia patients.
The emerging drugs in the Chemotherapy Induced Anemia market are
- Roxadustat (FG-4592)
- Desidustat, and others
Chemotherapy Induced Anemia Key Players
The key players working in the Chemotherapy Induced Anemia market are
- Aileron Therapeutics
- Zydus Cadila, and others